Allspring Global Investments Holdings LLC Has $9.15 Million Stock Position in Icon Plc $ICLR

Allspring Global Investments Holdings LLC cut its stake in Icon Plc (NASDAQ:ICLR) by 92.4% during the 1st quarter, HoldingsChannel.com reports. The fund owned 82,135 shares of the medical research company’s stock after selling 998,057 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Icon were worth $9,151,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Toth Financial Advisory Corp bought a new position in Icon during the 4th quarter worth approximately $27,000. EFG International AG bought a new stake in shares of Icon in the 4th quarter valued at $27,000. Abound Financial LLC bought a new stake in shares of Icon in the 4th quarter valued at $54,000. Johnson Financial Group Inc. acquired a new stake in shares of Icon during the third quarter worth $71,000. Finally, Blue Trust Inc. increased its position in shares of Icon by 207.5% during the first quarter. Blue Trust Inc. now owns 658 shares of the medical research company’s stock worth $73,000 after buying an additional 444 shares during the period. Institutional investors and hedge funds own 95.61% of the company’s stock.

Icon Stock Performance

Shares of ICLR opened at $167.28 on Thursday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.14 and a quick ratio of 1.14. The stock has a 50-day moving average of $149.05 and a 200-day moving average of $136.36. The company has a market cap of $12.81 billion, a PE ratio of 29.77, a P/E/G ratio of 8.18 and a beta of 1.22. Icon Plc has a one year low of $66.57 and a one year high of $211.00.

Analyst Ratings Changes

Several research firms recently issued reports on ICLR. Barclays boosted their target price on shares of Icon from $160.00 to $175.00 and gave the company an “equal weight” rating in a report on Thursday, June 25th. Citigroup increased their price target on Icon from $140.00 to $165.00 and gave the stock a “neutral” rating in a report on Thursday, June 25th. BMO Capital Markets lifted their price objective on Icon from $160.00 to $187.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Bank of America boosted their price objective on Icon from $125.00 to $150.00 and gave the company an “underperform” rating in a research note on Thursday, June 25th. Finally, Leerink Partners set a $145.00 target price on Icon in a research report on Thursday, May 28th. Nine investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $173.19.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.